Bioengineering & Translational Medicine最新文献

{"title":"A silicon membrane microfluidic oxygenator for use as an artificial placenta with minimal anticoagulation","authors":"David G. Blauvelt, Nicholas C. Higgins, Anne Hesek, Bianca N. De, Nathan Wright, Prasad Nithianandam, Charles Blaha, Jarrett Moyer, Benjamin W. Chui, Francisco J. Baltazar, Shuvo Roy","doi":"10.1002/btm2.70037","DOIUrl":"https://doi.org/10.1002/btm2.70037","url":null,"abstract":"Extreme prematurity carries a high burden of morbidity and mortality. The artificial placenta is an emerging therapy that has the potential to improve outcomes in these patients. However, current devices in development are limited by inadequate hemocompatibility, a major barrier to the translation of the artificial placenta into humans. Here, we present a novel microfluidic oxygenator that is comprised of a stacked array of semiconductor silicon membranes and operates with minimal anticoagulation (activated clotting time = 120–180 s). We describe the design, construction, and testing of two generations of prototypes. Our Generation 2 Device had an oxygen transfer of 1.51 ± 0.25 volume % (mean ± standard error). Computational fluid dynamics (CFD) modeling demonstrated favorable blood flow properties, including laminar flow, no stasis or recirculation, and optimal wall shear stress. In vivo testing in a 6 hour neonatal swine model showed that the silicon membrane oxygenator could operate with low‐dose anticoagulation with minimal clot formation. Furthermore, the oxygenator had no significant effect on markers of animal health, including inflammation (white blood cell count), coagulation (platelet count, prothrombin time), or hemolysis (hematocrit, plasma free hemoglobin). This study represents a key advance toward developing an anticoagulation‐free oxygenator and ultimately bringing artificial placenta technology to patients.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"107 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144611070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing nephrocalcinosis treatment: IL‐10 engineered macrophages as a novel therapeutic approach","authors":"Wenlei Zhao, Kailong Wang, Hairui Chen, Junnan Xu, Lequan Wen, Yan Wu, Weihao Chen, Haitao Liu, Yanzhong Liu, Jiqing Zhang, John C. Lieske, Luo Zhang, Xu Zhang, Haixing Mai","doi":"10.1002/btm2.70047","DOIUrl":"https://doi.org/10.1002/btm2.70047","url":null,"abstract":"Nephrocalcinosis provides a nidus for stone formation and is strongly linked to renal injury and chronic kidney disease. Although the crucial role of macrophages in the formation and progression of calcium oxalate (CaOx) crystals has long been widely recognized, finding effective immunotherapies for nephrocalcinosis remains a challenge. In this study, we described an innovative macrophage‐based method that delivers interleukin‐10 (IL‐10) into the kidney, reduces the deposition of CaOx crystals, and alleviates renal injury in a mouse model of glyoxylate‐induced CaOx. Compared with recombinant IL‐10 direct injection, the macrophage‐based method has the advantages of biocompatibility and sustaining action. We found that the transplantation of engineered macrophages via the tail vein significantly reduced the volume of crystals in the kidney, thereby alleviating the kidney injury caused by crystal. In mechanistic studies, IL‐10‐secreting macrophages inhibited crystal formation and promoted crystal clearance by promoting macrophage M2 polarization, exerting a protective effect on renal tissue. Our data suggest that macrophage‐based delivery of IL‐10 to the kidney can be a potential treatment method for nephrocalcinosis.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"329 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144603231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"USENSE: A proof‐of‐concept self‐screening tool for home‐based recurrent urinary tract infection management","authors":"Antra Ganguly, Ujjaini Basu, Varun Gunda, Ashwin Krishnan, Pranav Ramesh, Kush Jivnani, Arjun Raghuram, Shashank Bhagavatula, Sifa Khan, Philippe Zimmern, Nicole De Nisco, Shalini Prasad","doi":"10.1002/btm2.70038","DOIUrl":"https://doi.org/10.1002/btm2.70038","url":null,"abstract":"In this work, we report a novel proof‐of‐concept biosensing diagnostic tool for the multiplexed electrochemical quantitation of a unique combination of three <jats:styled-content style=\"fixed-case\">UTI</jats:styled-content>‐relevant biomarkers, Prostaglandin <jats:styled-content style=\"fixed-case\">E2</jats:styled-content> (<jats:styled-content style=\"fixed-case\">PGE2</jats:styled-content>), Interleukin‐8 (<jats:styled-content style=\"fixed-case\">IL</jats:styled-content>‐8), and Lipopolysaccharide (<jats:styled-content style=\"fixed-case\">LPS</jats:styled-content>), in unfiltered human urine. The proposed device, called <jats:styled-content style=\"fixed-case\">USENSE</jats:styled-content>, integrates lateral flow microfluidic channels, a gold‐based sensor array for quantifying <jats:styled-content style=\"fixed-case\">PGE2</jats:styled-content>, <jats:styled-content style=\"fixed-case\">IL</jats:styled-content>‐8, and <jats:styled-content style=\"fixed-case\">LPS</jats:styled-content> levels, and a random forest machine learning model for reliable diagnosis of <jats:styled-content style=\"fixed-case\">UTI</jats:styled-content>. The device is unique as it not only acts as a diagnostic device but also provides information on <jats:styled-content style=\"fixed-case\">UTI</jats:styled-content> by providing a risk score for <jats:styled-content style=\"fixed-case\">UTI</jats:styled-content> recurrence. <jats:styled-content style=\"fixed-case\">USENSE</jats:styled-content> is culture‐free and label‐free, requires no sample preparation at the user end, and can be adapted for use in home‐based self‐screening. In less than 5 minutes, <jats:styled-content style=\"fixed-case\">USENSE</jats:styled-content> directly measures the urinary concentration of <jats:styled-content style=\"fixed-case\">PGE2</jats:styled-content>, <jats:styled-content style=\"fixed-case\">IL</jats:styled-content>‐8, and <jats:styled-content style=\"fixed-case\">LPS</jats:styled-content> and provides a <jats:styled-content style=\"fixed-case\">UTI</jats:styled-content> severity state classification: 0 = Healthy, 1 = Asymptomatic Bacteriuria, 2 = Symptomatic; low risk of relapse, 3 = Symptomatic; high risk of <jats:styled-content style=\"fixed-case\">UTI</jats:styled-content> relapse. In postmenopausal women, the <jats:styled-content style=\"fixed-case\">PGE2</jats:styled-content>, <jats:styled-content style=\"fixed-case\">IL8</jats:styled-content>, and <jats:styled-content style=\"fixed-case\">LPS</jats:styled-content> concentrations measured via the device correlated well with the levels measured using traditional enzyme‐linked immunosorbent assay (<jats:styled-content style=\"fixed-case\">ELISA</jats:styled-content>). Our machine learning diagnostic model allowed for <jats:styled-content style=\"fixed-case\">UTI</jats:styled-content> diagnosis with 93% test accuracy and <jats:styled-content style=\"fixed-case\">UTI</jats:styled-content> prognosis state classification with >84% accuracy for the human urine samples tested. ","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"694 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144603274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient‐specific visco‐hyperelastic mechanical model for breast tumor localization in surgical planning","authors":"Felicia Alfano, Pedro Navas, Pablo Lamata, Karla Ferreres García, Juan E. Ortuño, Oscar Bueno Zamora, Santiago Lizarraga, Andrés Santos, Javier Pascau, José M. Goicolea, María J. Ledesma‐Carbayo","doi":"10.1002/btm2.70044","DOIUrl":"https://doi.org/10.1002/btm2.70044","url":null,"abstract":"Breast‐conserving surgery is typically performed with the patient in a supine position, whereas preoperative diagnostic MRI breast images are obtained with the patient in a prone position. The change in patient positioning causes significant large deformations, requiring preoperative localization of the detected lesions. Developing an individual‐specific breast biomechanical model capable of simulating these deformations remains challenging yet highly desirable. This study presents a novel approach that combines finite element analysis with the optimization of mechanical properties of breast tissues, using only surface information to construct a personalized deformation model of the breast. A visco‐hyperelastic model is employed to characterize the stress–strain relationship of breast tissue. The proposed method has been tested on 15 cases of breast cancer and achieves a tumor localization error of 8.12 ± 4.15 mm. The results show that this approach provides an accurate and realistic estimation of large breast tissue deformations and yields smaller tumor localization errors compared to previously reported methods.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"43 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144594116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ex vivo single‐cell profiling of acute myocardial infarction patients reveals disproportionate CD66b+ cell secretion response","authors":"Kerwin Kwek Zeming, Ri Lu, Elizabeth Lee, Ka‐Wai Cheung, Nicholas W. S. Chew, Kai Lee Woo, Lih Feng Cheow, Jongyoon Han, Shir Lynn Lim","doi":"10.1002/btm2.70043","DOIUrl":"https://doi.org/10.1002/btm2.70043","url":null,"abstract":"Acute myocardial infarction (AMI), a leading cause of death globally, triggers complex inflammatory responses critical to patient outcomes. However, rapid tools for profiling immune responses at the single‐cell level are lacking. The integrated Single‐cell Enzyme and Antigen Quantification (iSEAQ) system addresses this gap by enabling high‐throughput, single‐cell analysis of immune cell activity using just 20 μL of blood. This novel tool processes live CD66b and CD3 cells to quantify the secretion of Granzyme B, Neutrophil Elastase, and CD31 within minutes. Longitudinal studies on nine AMI patients revealed that CD66b<jats:sup>+</jats:sup> cells are major contributors (up to 95%) to key inflammatory enzymes, including the unexpected secretion of Granzyme B. iSEAQ achieves unparalleled sensitivity (0.4 fg/cell) and predictive accuracy (&gt;90%) for patient profiling across AMI onset, treatment, and discharge. This innovation provides clinicians with a rapid, precise method to monitor immune responses, unveiling new insights into AMI inflammation and therapy.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"43 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144577990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoxia‐preconditioned MiotEVs from bone marrow mesenchymal stem cells inhibit myocardial infarction‐induced cardiac fibrosis","authors":"Jungang Nie, Hongwen Zhu, Zhiming Gao, Liang Wang","doi":"10.1002/btm2.70046","DOIUrl":"https://doi.org/10.1002/btm2.70046","url":null,"abstract":"Hypoxia‐preconditioned bone marrow mesenchymal stem cell‐derived mitochondrial extracellular vesicles (Hypoxia‐BMSC MitoEVs) emerged as a novel therapeutic candidate for myocardial infarction (MI)‐induced cardiac fibrosis. Here, we demonstrate that MitoEVs isolated from hypoxic BMSCs, rich in intact mitochondria and the RNA‐binding protein Quaking (QKI), potently inhibited TGF‐<jats:italic>β</jats:italic>1‐driven myofibroblast activation in vitro by suppressing <jats:italic>α</jats:italic>‐SMA and collagen expression while restoring mitochondrial oxidative phosphorylation and metabolic balance. In a murine MI model, systemic delivery of Hypoxia‐BMSC MitoEVs attenuated cardiac fibrosis, reduced infarct size, and improved left ventricular function. Pharmacological inhibition of mitochondrial ATP synthase in MitoEVs similarly diminished their therapeutic efficacy. Mechanistically, MitoEVs delivered QKI protein to cardiac fibroblasts, where it inhibited translation of fibrotic mRNAs via m7G‐modified RNA interactions. Genetic ablation of QKI in BMSCs abrogated MitoEV‐mediated antifibrotic effects both in vitro and in vivo, confirming QKI as a critical effector. These results suggested that both QKI‐driven translational suppression and mitochondrial bioenergetics underpin their antifibrotic action. These findings highlight Hypoxia‐BMSC MitoEVs as a therapeutic strategy to mitigate post‐MI fibrosis, warranting further exploration for clinical translation.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"42 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144566559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancement of spinal cord injury repair in rats using photo‐crosslinked GelMA hydrogel combined with mitochondrial transplantation","authors":"Wenyong Gao, Can Tang, Diancheng Hang, Hao Chen, Dongsheng Li, Youjie Yan, Wuchang Wang, Hao Peng, Xianmin Wang, Enpeng Zhang, Min Wei, Hengzhu Zhang, Xiaodong Wang","doi":"10.1002/btm2.70040","DOIUrl":"https://doi.org/10.1002/btm2.70040","url":null,"abstract":"Acute spinal cord injury (SCI) induces mitochondrial oxidative stress, cellular bioenergetic crises, impaired protein degradation, and subsequent degeneration, resulting in increased neuronal vulnerability. Transplantation of exogenous mitochondria to the injury site mitigates cellular energy crises and counteracts neurodegeneration; however, the limited efficacy of mitochondrial transplantation alone constrains its therapeutic potential. In this study, we established a right‐sided spinal cord hemisection model at the T10 thoracic segment in rats and transplanted a methacrylate‐based gelatin (GelMA) hydrogel containing active mitochondria at the injury site to assess its therapeutic effects and underlying mechanisms. Our findings indicate that GelMA hydrogel combined with mitochondrial transplantation provides superior therapeutic benefits for SCI compared to mitochondrial transplantation alone. GelMA hydrogel enables sustained mitochondrial release at the injury site, supplying energy, upregulating NF200 expression, and promoting axonal regeneration. Additionally, it enhances M2 macrophage accumulation and improves the local inflammatory microenvironment. The structural framework of GelMA hydrogel further supports axonal regeneration. Footprint gait analysis and Basso, Beattie, and Bresnahan (BBB) motor scoring demonstrated that GelMA hydrogel combined with mitochondrial transplantation significantly improves motor function in the right hind limb of rats with SCI. Consequently, GelMA hydrogel combined with mitochondrial transplantation offers a viable and promising approach for treating spinal cord injury.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"154 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144547102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular vesicles from glucocorticoids‐preconditioned synovial mesenchymal stem cells exert antiarthritic effects by downregulating the mRNA m6A modification of NLRP3 in macrophages through miR‐212‐5p","authors":"Xiaolong Shao, Ming Zhang, Shouye Hu, Zhi Yang","doi":"10.1002/btm2.70042","DOIUrl":"https://doi.org/10.1002/btm2.70042","url":null,"abstract":"Osteoarthritis (OA) is a prevalent chronic degenerative joint disease with no known treatment for reversing its progression. However, recent studies have shown promising results for nano‐sized extracellular vesicles derived from preconditioned synovial mesenchymal stem cells (SMSCs) in treating various diseases, including OA. Glucocorticoids (GCs) possess potent anti‐inflammatory properties, but their long‐term use is limited due to potential adverse reactions. Building on previous research, this study aimed to investigate the therapeutic potential of extracellular vesicles secreted from GCs‐pretreated SMSCs (GCs‐EVs) in exerting antiarthritic effects. The results demonstrated that GCs‐EVs effectively inhibited cartilage degeneration and osteophyte formation in the OA mouse model by suppressing the release of inflammatory cytokines from synovial macrophages. This effect was attributed to the high expression of miR‐212‐5p in GCs‐EVs, which specifically inhibited the expression of methyltransferase‐like 3 (Mettl3). Consequently, the mRNA N6‐methyladenosine (m<jats:sup>6</jats:sup>A) level of nod‐like receptor pyrin domain 3 inflammasome (NLRP3) in macrophages was reduced, leading to decreased NLRP3 inflammasome activity and increased antiarthritic effects. Furthermore, in the co‐culture system, GCs‐EVs enhanced chondrocyte proliferation and migration while inhibiting chondrocyte apoptosis by suppressing the secretion of inflammatory factors by macrophages.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"19 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144533087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optogenetic modulation of peripheral nociceptive neurons with biocompatible optoelectronic implants","authors":"Paul Chu Sin Chung, Valentina Paggi, Marie Pertin, Guylène Kirschmann, Elena A. Konnova, Frédéric Michoud, Ivan Furfaro, Bernard L. Schneider, Stéphanie P. Lacour, Isabelle Decosterd","doi":"10.1002/btm2.70034","DOIUrl":"https://doi.org/10.1002/btm2.70034","url":null,"abstract":"Hyperexcitability of peripheral sensory neurons plays a critical role in the development and maintenance of chronic pain. Pharmacological analgesics used in clinics reduce neuronal activity. They often come with non‐negligible side effects. Optogenetic approaches can modulate neuronal activity and are attracting growing interest for therapeutic uses, but the delivery of light in different parts of the body requires the development of specific optoelectronic interfaces. We designed and produced a microfabricated optoelectronic implant to deliver yellow light (559 nm) onto the sciatic nerve. We have surgically implanted the device in transgenic mice expressing the yellow light‐sensitive inhibitory archaerhodopsin (ArchT) in nociceptive neurons. Yellow light induced a significant reduction in the responses of the nociceptive neurons and curbed the behavioral responses to noxious mechanical and thermal stimuli. Remarkably, the yellow light‐related inhibition did not alter the behavioral responses evoked by innocuous mechanical stimulation or by intense inflammation. The optoelectronic implants showed reliable and reproducible opto‐electrical performance. For stimulation parameters used in vivo (3.3 V, 60–80 mW/mm<jats:sup>2</jats:sup>, 20 s train pulses, 1 Hz, 80% duty‐cycle, and an inter‐train interval of 1 s), limited temperature increase was measured in an environment mimicking neural tissue surrounded by muscle and fat. Similarly, the basal sensitivity of the implanted mice remains comparable to non‐implanted mice, suggesting a safe integration of the soft electronic device. Our study confirmed that optoelectronic implants tailored to the sciatic nerve can provide specific light spectra and intensities at adequate levels for the optogenetic actuator to trigger significant electrophysiological and behavioral responses in pain perception.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"1 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144500579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dissecting contributions of pulmonary arterial remodeling to right ventricular afterload in pulmonary hypertension","authors":"Sunder Neelakantan, Emilio A. Mendiola, Byron Zambrano, Alexander Vang, Kyle J. Myers, Peng Zhang, Gaurav Choudhary, Reza Avazmohammadi","doi":"10.1002/btm2.70035","DOIUrl":"https://doi.org/10.1002/btm2.70035","url":null,"abstract":"Pulmonary hypertension (PH) is defined as an elevation in the right ventricular (RV) afterload, characterized by increased hemodynamic pressure in the main pulmonary artery (PA). Elevations in RV afterload increase RV wall stress, resulting in RV remodeling and potentially RV failure. From a biomechanical standpoint, the primary drivers for RV afterload elevations include increases in pulmonary vascular resistance (PVR) in the distal vasculature and decreases in vessel compliance in the proximal arteries. However, the individual contributions of the various vascular remodeling events toward the progression of PA pressure elevations and altered vascular hemodynamics remain elusive. In this study, we used a subject‐specific one‐dimensional (1D) fluid–structure interaction (FSI) model to investigate the alteration of pulmonary hemodynamics in PH and to quantify the contributions of decreased compliance and increased resistance toward increased main pulmonary artery (MPA) pressure. We used a combination of subject‐specific hemodynamic measurements, ex‐vivo mechanical testing and histological analysis of arterial tissue specimens, and ex‐vivo x‐ray micro‐tomography imaging to develop the 1D FSI model and dissect the contribution of PA remodeling events toward alterations in the MPA pressure waveform. Both the amplitude and pulsatility of the MPA pressure waveform were analyzed. Our results indicated that increased distal resistance has the greatest effect on the increase in maximum MPA pressure, while decreased vessel compliance caused significant elevations in the characteristic impedance. The method presented in this study will serve as an essential step toward understanding the complex interplay between PA remodeling events that lead to the most adverse effect on RV function.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"65 1","pages":""},"PeriodicalIF":7.4,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144500578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}